CatalystMarker
← board

LIMNW

distress 5/10 · elevated risk
$0.04-23%today-46% from 52w high
liminatuspharma.com1 employeesFounded 2018Cerritos, CA
Revenue
pre-revenue
Liquidity
$0M
Runway
—
Shares 1y
+66%

Price & events

-45.7% over 6M
$0.04$0.06$0.08Mar 26May 26Jul 26700dilution: S-1 shelf_registration (2026-06-24)dilution: 424B3 offering (2026-06-03)financing: 8-K private_placement (2026-07-06)financing: 8-K private_placement (2026-06-03)financing: 8-K material_agreement (2026-05-20)
CatalystRating changeDilutionFinancingdashed = today
-22.7%
1D
-28.5%
1W
-28.5%
1M
-28.5%
3M
—
6M
—
1Y
—
2Y
—
5Y
-45.7%
All

Overview

Market Cap
$1.93M
Volume
298
52 Week Range
$0.04 – $0.08
Total Shares
44.88M
Float Shares
27.11M
RVOL
8.96x
Beta
0.74

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 44,877,633 · 3 offerings/1y · 3 PIPEs
  • 2026-07-068-Kprivate_placement
  • 2026-06-24S-1shelf_registration
  • 2026-06-038-Kprivate_placement
  • 2026-06-03424B3offering
  • 2026-05-208-Kmaterial_agreement
  • 2026-02-188-Kmaterial_agreement
  • 2026-02-18424B4offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.